drugset
drugset / Trial / NCT05511025

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

NCT05511025 ↗

Phase 1 Completed 54 enrolled AstraZeneca
RandomizedSequentialDouble-blindTreatment

Summary

A study in healthy male and female participants of non-childbearing potential who are overweight or obese.

Timeline

Start
2022-09-20
Primary completion
2023-12-19
Completion
2023-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD6234 Small activating RNA (saRNA) — Subcutaneous
Background Acetaminophen Small molecule — —

Indications

No indication recorded.